Vildagliptin Market: North America to Capture Major Share of Global Market

Vildagliptin Market: Introduction

Vildagliptin is an antihyperglycemic medication that inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme selectively. It is used to treat type 2 diabetes mellitus, which is characterized by impaired GLP-1 production and insulinotropic effects. DPP-4 is inhibited. Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), both incretin hormones that stimulate insulin production and control blood glucose levels, are protected from breakdown by vildagliptin. GLP-1 and GIP levels are elevated, which leads to better glycemic control. Vildagliptin has been shown in clinical studies to have a minimal risk of hypoglycemia.

Read Report Overview -

The European Medicines Agency authorized oral vildagliptin for the treatment of type 2 diabetes mellitus in adults as monotherapy or in combination with metformin, a sulfonylurea, or a thiazolidinedione in patients with insufficient glycemic control after monotherapy in 2008. Galvus is the brand name for it. For individuals who do not achieve sufficient glycemic control with monotherapy, vildagliptin is now available as Eucreas, a fixed-dose formulation with metformin. In the U.S., vildagliptin is being investigated.

Key Drivers, Restraints, and Opportunities of Global Vildagliptin Market

The vildagliptin market is projected to be driven by an increase in disease prevalence and clinicians' efforts to postpone disease development and minimize the costly burden of diabetes complications through the use of combination treatments.

Request Brochure of Report -

As per WHO, the number of people with diabetes rose from 108 million in 1980 to 422 million in 2014, this number is estimated to rise to 700 million by 2045. 374 million people are at an increased risk of developing type 2 diabetes. Prevalence has been rising more rapidly in low- and middle-income countries than in high-income countries. In 2019, an estimated 1.5 million deaths were directly caused by diabetes.

Another 2.2 million deaths were attributable to high blood glucose in 2015. According to the CDC, gestational diabetes can impact 4.6% to 9.2% of pregnancies during pregnancy and parenthood. In up to 10% of cases, the woman is diagnosed with type 2 diabetes shortly after giving birth. Within 10 to 20 years, the rest of these women had a 35% to 60% risk of acquiring type 2 diabetes. This is likely to boost the vildagliptin market. Older age; excess weight, particularly around the waist; family history; certain ethnicities; physical inactivity; and poor diet also increase the incidences of type 2 diabetes. All these factors lead to higher incidences of type 2 diabetes, which in turn fuels the vildagliptin market.

Request for Custom Research -

North America to Capture Major Share of Global Vildagliptin Market

North America is expected to account for a major share of the global vildagliptin market, due to technological advancements, presence of major players, and a rise in prevalence of type 2 diabetes in the region. More than 34 million people in the U.S. have diabetes, and approximately 90% to 95% of them have type 2 diabetes. Type 2 diabetes most often develops in people over age 45; however, an increasing number of children, teens, and young adults are also developing it.

The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to an increase in prevalence of diabetes in the region. Presence of a large number of vildagliptin manufacturers in Asia is another factor that is projected to propel the market in the region.

Pre Book Vildagliptin Market Report at

Key Players Operating in Global Vildagliptin Market

The global vildagliptin market is highly consolidated with the presence of key players. A large number of manufacturers hold a major share in their respective regions. Major players operating in the global vildagliptin market include:

  • Actis Generics Pvt Ltd.
  • Cipla
  • Eris Lifesciences
  • Farmavita
  • Medochemie
  • Metrochem API Pvt Ltd
  • Novartis

Browse more Reports by Transparency Market Research: 

In Vitro Diagnostics Market: The demand within the global in-vitro diagnostics market is set to rise at a sturdy pace in the times to follow. It has become crucial for the healthcare industry to ensure optimal growth in multiple domains.

Sterility Testing Market: Growth of the sterility testing market is attributed to rising population, technological advancements in rapid sterility test, increase in healthcare expenditure, favorable healthcare insurance coverage, rising prevalence of chronic and rare diseases.

Intraocular Lens Market: The global intraocular lens market is likely to witness high growth opportunities birthing with the rise in prevalence of cataract all across the world. An intraocular lens replaces the natural lens for better focusing power.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453

Back to news